FGFR inhibitors that irreversibly bind to FGFR2 (e.g. futibatinib, RLY-4008) may have greater antitumor activity in CCA with FGFR2 resistance mutations compared with ATP-competitive inhibitors (e.g. pemigatinib).14 Here, FGFR2 is linked to cholangiocarcinoma.